Warfarin-5-FU interactions [3]

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 176-

  Giunta, Giovanni ^a  

^a Laboratorio di Patologia Clinica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUOROURACIL; FOLINIC ACID; LIPID; METHOTREXATE; OXALIPLATIN; OXIDOREDUCTASE; STEROID; VITAMIN; WARFARIN;

ANTICOAGULATION; BIOSYNTHESIS; BLEEDING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LIVER METABOLISM; LONG TERM CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RETROSPECTIVE STUDY;

EID: 29844433861     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj001     Document Type: Letter

References (7)

1. Masci G, Magagnoli M, Zuccali PA et al. Minodose warfarin prophylaxis for catheter associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003; 21: 736-739.
2. Magagnoli M, Masci G, Carnaghi C et al. Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen. Ann Oncol 2003; 14: 959-960.
3. Kuter DJ. In reply: Low dose warfarin prophylaxis for catheter associated thrombosis in cancer patients. Can be safely associated with 5-fluorouracil-based chmotherapy? Oncologist 2004; 9: 596.
4. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247-252.
5. Copur MS, Ledakis P, Bolton M et al. An adverse interaction between warfarin and capecitabine: A case report and review of the literature. Clin Colorectal Cancer 2001; 1:182-184.
6. Giunta G, Velluti F. Subdural haematoma of the brain due to a possible interaction between warfarin and 5 fluorouracil. J Pharm Technol 2004; 20: 77-79.
7. Malacarne P, Maestri A. Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities. Recenti Prog Med 1996; 87: 135.